Up to date, patient subgroups with non-small cell lung cancers due to the mutation in the anaplastic lymphoma kinase (ALK), BRCA mutant-ovary cancer, breast cancer with human epidermal growth factor receptor 2 (HER2) overexpression have already benefited from precision medicine with targeted therapies (Vogel et al., 2002; Neff et al., 2017; Qin and Gadgeel, 2017). This evidence concerns the gene ERBB2 and ovarian cancer.